Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
RZLT 
Rezolute Inc (RZLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/29/2025: RZLT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.12
1 Year Target Price $4.12
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.46% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 225.33M USD | Price to earnings Ratio - | 1Y Target Price 4.12 |
Price to earnings Ratio - | 1Y Target Price 4.12 | ||
Volume (30-day avg) 10 | Beta 0.22 | 52 Weeks Range 1.07 - 11.46 | Updated Date 12/29/2025 |
52 Weeks Range 1.07 - 11.46 | Updated Date 12/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.68% | Return on Equity (TTM) -59.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 96842510 | Price to Sales(TTM) - |
Enterprise Value 96842510 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.01 | Shares Outstanding 92727532 | Shares Floating 64667254 |
Shares Outstanding 92727532 | Shares Floating 64667254 | ||
Percent Insiders 10.52 | Percent Institutions 109.45 |
Upturn AI SWOT
Rezolute Inc
Company Overview
History and Background
Rezolute Inc. (formerly Primech Holdings Limited) was founded in 2013. It has undergone significant transformation, shifting its focus from industrial automation and engineering services to becoming a clinical-stage biopharmaceutical company. A key milestone was its rebranding and strategic pivot towards developing novel therapies for metabolic and cardiovascular diseases.
Core Business Areas
- Biopharmaceutical Research and Development: Rezolute Inc. is focused on the discovery, development, and commercialization of novel therapeutic solutions for a range of diseases. Its primary focus is on metabolic diseases such as diabetes, obesity, and related cardiovascular complications.
Leadership and Structure
The company is led by a management team with experience in drug development and business operations. Specific individuals and their roles can be found on the company's investor relations pages.
Top Products and Market Share
Key Offerings
- RP101 (Imeglimin): RP101 is an orally administered, small molecule drug designed to improve insulin secretion, enhance insulin sensitivity, and reduce glucotoxicity. It is being developed for the treatment of type 2 diabetes and potentially other metabolic disorders. Market share data for RP101 is not yet established as it is in clinical development. Key competitors in the type 2 diabetes market include companies developing GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors.
- RP301: RP301 is another investigational drug candidate targeting metabolic diseases. Further details on its specific mechanism of action and development stage are available in company filings. Market share is not yet applicable.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on metabolic and cardiovascular diseases, is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. There is a growing demand for innovative treatments for chronic conditions like diabetes and obesity, driven by increasing prevalence and associated healthcare burdens.
Positioning
Rezolute Inc. is positioning itself as a developer of novel therapies that address unmet needs in metabolic disease treatment. Its competitive advantage lies in its unique drug candidates and their potential to offer new therapeutic approaches.
Total Addressable Market (TAM)
The global market for diabetes and obesity treatments is substantial and projected to continue growing significantly. Rezolute Inc. aims to capture a portion of this market with its innovative drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potential to address unmet needs.
- Experienced management team in drug development.
- Focus on a large and growing market (metabolic diseases).
Weaknesses
- Clinical-stage company with no approved products.
- High R&D costs and inherent risks of drug development.
- Limited financial resources compared to established pharmaceutical giants.
Opportunities
- Growing prevalence of diabetes and obesity globally.
- Advancements in understanding metabolic pathways.
- Potential for strategic partnerships and collaborations.
Threats
- Failure in clinical trials.
- Regulatory delays or rejections.
- Intense competition from established pharmaceutical companies.
- Patent expirations and generic competition for existing treatments.
Competitors and Market Share
Key Competitors
- Eli Lilly and Company (LLY)
- Novo Nordisk A/S (NVO)
- Sanofi (SNY)
- Merck & Co., Inc. (MRK)
- Pfizer Inc. (PFE)
Competitive Landscape
Rezolute Inc. faces a highly competitive landscape dominated by large pharmaceutical companies with established R&D capabilities, extensive commercial infrastructure, and diversified product portfolios. Rezolute's advantage lies in its potential to introduce novel mechanisms of action that could differentiate its therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Rezolute Inc. has been characterized by its transformation from a different industry to a biopharmaceutical focus, and by advancements in its clinical pipeline. Revenue growth is not a primary indicator at this stage.
Future Projections: Future growth projections are contingent on successful clinical trial outcomes for RP101 and RP301, regulatory approvals, and successful commercialization. Analyst estimates, if available, would reflect these developmental milestones.
Recent Initiatives: Recent initiatives likely involve progressing its lead drug candidates through clinical development phases, seeking regulatory feedback, and potentially securing strategic partnerships or funding to support its pipeline.
Summary
Rezolute Inc. is a clinical-stage biopharmaceutical company with a strong focus on metabolic diseases. Its main strength lies in its innovative drug candidates, RP101 and RP301, targeting a significant and growing market. However, it faces substantial risks due to its early-stage development, high R&D costs, and intense competition from established players. Successful clinical trials and regulatory approvals are critical for its future growth and viability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Rezolute Inc. SEC Filings (10-K, 10-Q)
- Financial News Websites
- Industry Research Reports
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Investment decisions should be made in consultation with a qualified financial advisor. Market share data and TAM estimates are subject to change and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rezolute Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-05-01 | Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Mr. Nevan Charles Elam J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 75 | Website https://www.rezolutebio.com |
Full time employees 75 | Website https://www.rezolutebio.com | ||
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.